2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $27M to $27.5M, increasing; diluted EPS 0.25 to -0.47, decreasing.
90
Median gross margin 63.4% over 10y, stable.
11
Median ROIC -5.3%, above the 12% hurdle in 30% of years.
55
Net cash position — no leverage risk.
24
Owner earnings changed trend unclear over up to the ten most recent annual observations.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
Above value if growth stopped todayBelow value if growth stopped today
2% below value if growth stopped today
$4.6M
$3.11
$3.11
$3.03
2% below value if growth stopped today
A discount this large is often a warning rather than a bargain — the market may expect earnings to keep falling. See the revenue trend above.
How to read this
What today’s price assumes: owner earnings shrinking ~1%/yr over 5 years. The estimate assumes owner earnings stay flat (0% growth).
We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
12 years of fundamentals
The business, in plain English
Sensus Healthcare, Inc. booked $27.5M of revenue in FY2025 in the Healthcare sector and kept 43.2% of it as gross profit — a solid-margin business by that measure. After every other cost, −28.1% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $10.3M (FY2015) to $27.5M (FY2025) — about 10.3% a year compounded over 10 years.
It earned −31.3% on invested capital in the latest filed year, FY2025. Across the full 11-year measurable filed record, median ROIC was −7.8%. Over the v3 recent window (10 measurable filed years), median ROIC was −5.3%. The Returns on Capital filter above scores it 11/100.
SRTS's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
Put together: Pricing Power is the strongest of the five filters (90/100) and Returns on Capital the weakest (11/100), which is how SRTS lands at 42/100 — a Shallow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
FY2014–FY2025 · 12 fiscal years, normalized from SRTS’s SEC filings
Sales, as filed$27.5M FY2025Revenue kept after cost of goods43.2% FY2025Standard ROIC or separately labeled Operating ROICROIC −31.3% FY2025Cash an owner could take out−$7.5M FY2025
Gaps in a line mean that item isn’t in SRTS’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Flagship explainer
How Sensus Healthcare, Inc. makes its money
Start with a dollar of revenue and follow what the filing says remains.
Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.
Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.
Records still being gathered — partial as of retrieval Aug 11, 2026.
Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.
Moat Score history
15 logged readings since Jul 17, 2026 · append-only, never rewritten
Moat Score over timeLast scored reading of each day, on the 0–100 scale42.0 / 100
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.
Records still being gathered — partial as of retrieval Aug 11, 2026.
Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.
No reported Form 4 rows were captured for SRTS; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.
A filing source-event date will appear when a Form 4 row is captured.
Retrieved .
Healthcare context
#319 of 728 scored Healthcare companies, ranked by Moat Score.
Does Sensus Healthcare, Inc. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Sensus Healthcare, Inc. (SRTS) 42.0 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 31, pricing power 90, returns on capital 11, balance-sheet safety 55, capital allocation 24.
Is SRTS trading below the conservative owner-earnings estimate?
The value if growth stopped today — a zero-growth baseline — is $3.11 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $3.03, that is 2% below value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has SRTS's Moat Score changed over time?
The record logs 15 readings since Jul 17, 2026; the latest reads 42.0 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.
Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell SRTS. See the disclaimer.